What is KPV? What it does, benefits and what the evidence shows

KPV is a synthetic tripeptide, lysine-proline-valine, matching the last three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH). It has never been approved as a drug anywhere, and the research behind it is almost entirely mouse colitis models and human cell cultures in a dish — not human trials. Researchers are interested in it mainly for inflammatory bowel disease and, more recently, airway inflammation, and in July 2026 an FDA advisory committee recommended it as one of six peptides for a list of substances compounding pharmacies could legally use, a recommendation that is not the same as approval.

What KPV is and how it works

Alpha-MSH is a hormone best known for its role in skin pigmentation, but researchers have long known that smaller fragments of the molecule keep some of its anti-inflammatory activity without its pigmentation effects. KPV is the smallest such fragment studied in any depth: just the C-terminal tripeptide, Lys-Pro-Val.

That distinction between the full hormone and its fragments matters, because alpha-MSH itself does far more than fight inflammation — it's the hormone behind skin pigmentation and one of several signals involved in appetite regulation, which is why larger, more receptor-active alpha-MSH analogs are studied and sold for tanning and weight effects. KPV, being just three of alpha-MSH's thirteen amino acids, was of interest specifically because early researchers found it kept meaningful anti-inflammatory activity while losing much of that broader hormonal profile. What makes KPV mechanistically interesting today is that its anti-inflammatory effect doesn't appear to run through the classic melanocortin receptors (MC1R, MC3R, and so on) that alpha-MSH itself uses. In a 2008 study in Gastroenterology, researchers found that KPV is taken up into intestinal epithelial and immune cells through PepT1, a transporter that normally moves small peptides from digested protein across the gut lining and that becomes more active in inflamed tissue (Dalmasso et al., Gastroenterology, 2008, via PMC). Once inside the cell, KPV at nanomolar concentrations suppressed NF-kappaB activation and reduced MAPK phosphorylation triggered by the inflammatory cytokine IL-1beta — signaling pathways that switch on a broad slate of inflammatory genes.

A separate 2012 study in cultured human bronchial epithelial cells found a related but distinct piece of the mechanism: competition assays pointed to KPV interfering with the binding site where the NF-kappaB subunit p65RelA meets an importin protein needed to carry it into the cell nucleus, suppressing NF-kappaB signaling; the authors describe this as a possible blockade of the importin (Land, International Journal of Physiology, Pathophysiology and Pharmacology, 2012, via PMC). The same paper found a related alpha-MSH fragment, gamma-MSH, working through MC3R on airway cells to calm inflammatory signaling triggered by TNF-alpha and respiratory syncytial virus — a reminder that "melanocortin peptide" covers several different mechanisms depending on which fragment and which receptor is involved.

None of this is a description of what KPV does in a living person. It's a description of what happens inside mouse colons and cultured human cells in a lab.

Why the receptor question matters practically: alpha-MSH and its larger, more receptor-active analogs (the melanotan compounds) are associated with skin tanning and appetite suppression, both driven by melanocortin receptor activation. Because the Dalmasso and Land papers both describe KPV's anti-inflammatory activity as running mainly through non-receptor pathways (PepT1 transport and direct interference with NF-kappaB's route into the nucleus), researchers have inferred that KPV shouldn't produce those melanocortin-driven effects the way a full alpha-MSH analog would. That's a reasonable inference from the mechanism papers, but it's an inference, not something anyone has tested directly in a person taking KPV — nobody has published a study checking whether it causes pigmentation or appetite changes in practice.

What people use it for

What the research actually shows

Gut inflammation — two independent mouse-colitis studies

The strongest, most-replicated finding for KPV is in mouse models of inflammatory bowel disease, and it comes from two separate research groups using different colitis models. Dalmasso and colleagues used both DSS-induced colitis and TNBS-induced colitis in mice, and KPV given in the drinking water cut myeloperoxidase activity (a marker of tissue neutrophil infiltration) by about 50% in the DSS model and about 30% in the TNBS model, and reduced histological inflammation in both. Colon cytokine mRNA fell too: in the DSS model the drop was statistically significant for IL-6 and IL-12, and in the TNBS model for IL-1beta, IL-6, TNF-alpha and interferon-gamma (Dalmasso et al., 2008).

A second group tested KPV in two mouse models, DSS colitis and CD45RB-transfer colitis, and found earlier recovery and stronger regain of body weight, with reduced inflammatory infiltrate on histology. Notably, they also tested KPV in mice bred to lack a functional MC1 receptor and found KPV still rescued all of the treated animals from death during DSS colitis — direct evidence that at least part of KPV's effect in the gut doesn't depend on the melanocortin receptor most associated with alpha-MSH (Kannengiesser et al., 2008). That MC1R-independence lines up with the PepT1-mediated mechanism described above.

We found no published trial testing KPV, in any form, in a person with IBD, colitis, or any other gut condition.

Airway inflammation — human cells in a dish, not human lungs

The airway finding is a genuine data point, but it's worth being precise about what kind of data it is: immortalized human bronchial epithelial cells growing in culture, not a person breathing. Land's 2012 study measured NF-kappaB reporter activity, interleukin-8 and eotaxin secretion, and matrix metalloproteinase-9 activity in these cells, and found KPV suppressed the NF-kappaB pathway they'd triggered experimentally (Land, 2012). That's a plausible mechanism for why researchers are curious about melanocortin peptides in inflammatory lung disease. It is not evidence that KPV does anything for a person's airway.

Human data: none published

As far as we could verify, there is no published clinical trial of KPV in humans, for any condition. A Phase I safety study in healthy volunteers, followed by a small proof-of-concept trial, would be the logical next step, and we found no sign that either has been published. Until it does, everything said about what KPV does for a person is extrapolation from rodent and cell-culture data.

That gap is worth sitting with for a moment, because KPV's mouse data is genuinely stronger than the mouse data behind several better-known research peptides — two independent groups, two different colitis models, a survival benefit in receptor-knockout mice. It's a legitimate candidate for eventual human study. It just isn't one yet, and "strong animal data" and "works in people" are different claims that get blurred constantly in how this compound is marketed.

Side effects and risks

Because there's no published human trial, there's no published human safety data either — no adverse-event tables, no dose-finding study, nothing to point to beyond the animal and cell-culture work above, which wasn't designed to answer safety questions in people.

On the regulatory side, KPV was one of six peptides (with BPC-157, TB-500, MOTS-c, Epitalon and Semax) that the FDA Pharmacy Compounding Advisory Committee voted on July 23-24, 2026 to recommend for the 503A bulk drug substances list, the list of substances licensed compounding pharmacies are permitted to use (NCPA, July 31, 2026). That's a committee recommendation, not a final rule — the FDA still has to act on it, and even if it's adopted, inclusion on a compounding-substances list is not an approval of KPV as a drug for any specific use, and it says nothing about what's actually in a vial sold on the grey market.

It's worth being precise about what a 503A listing would and wouldn't change. If the FDA eventually finalizes that recommendation, licensed compounding pharmacies could legally prepare KPV under pharmacist oversight, from a substance meeting compounding-grade specifications, for a prescriber's patient. That's a fundamentally different supply chain from a research-chemical vial bought online with no prescription, no pharmacist, and no requirement that the seller test anything before shipping it — the two would exist side by side, and a 503A listing wouldn't retroactively make grey-market vials any more verified than they are today.

On the grey-market side, our data shows a genuinely small sample. Of 11 KPV vials in our database, 9 of 11 came in at 99% or higher, with a median purity of 99.68%; of the 10 vials with a measured amount, the median measured 12.2% over label, and 4 of those 10 measured more than 20% over. 0 of the 11 vials failed our definition (empty, under 95% pure, more than 20% under label, or more than 50% over). With a sample this small, a single new report can move these numbers noticeably.

What the lab tests show

As of September 30, 2026, our database includes 11 KPV vials from 9 vendors, drawn from 9 lab reports dated May 2025 through September 2026. It's one of the thinnest datasets we track, so treat the figures above as an early snapshot rather than a settled pattern. Here's how the ranked vendors for KPV look right now; the table shows current verdicts and flags any vendor whose failed-vial rate is above 5%. With this few total vials tested, this table may be short or empty:

Buying smarter

If you're evaluating a specific vendor's KPV, check their full record on our KPV results page — a vendor needs five or more lab reports before we rank them, and with a compound this thinly tested overall, the number of reports behind any score matters even more than usual. Treat a vendor-posted COA as a starting point rather than proof: how to read a peptide COA and fake peptide COAs cover what to check before trusting a number you didn't see tested yourself.

Given how little independent testing exists for this specific compound, how to get a peptide tested walks through ordering your own identity, purity and quantity results from a lab. Given that KPV shares part of its name and origin story with other alpha-MSH fragments and analogs, an identity test — confirming the vial actually contains the tripeptide it's labeled as, rather than a related melanocortin peptide sold under a similar name — is arguably as useful here as a purity or quantity check. If your report comes back with a fail, stop using that batch, tell anyone who bought from the same run, bring the report to the vendor, and submit it to VendorVerify — for a compound this thinly tested, one more test meaningfully changes the picture.

Database figures without a date update automatically from VendorVerify's lab results; dated figures are snapshots. This isn't medical advice; KPV is sold for research use only and has not been evaluated by FDA for safety or effectiveness in humans.